Stryker Emphasizes Overseas Opportunities, Difficulties
This article was originally published in The Gray Sheet
Stryker reported generally positive earnings and revenue for 2012 despite struggles in Europe. The company is reorganizing its European business while developing its strategy for emerging markets.
You may also be interested in...
Large Joint Replacement Market: Set For A Rebound?
Beaten down by the great recession, the large joint arthroplasty market appears to be on the cusp of a turnaround, with several big players reporting encouraging Q4 and full-year 2012 results. A full recovery in this space is likely to take some time, but technology advances could help jumpstart the process, and there may be some interesting dynamics ahead in the patient-specific implant and robotic ortho device arenas.
Device Trends To Watch In 2013
The prospective medical device tax, the continuing decline of venture investing, pricing challenges, austerity measures in Europe, and other headwinds continued to push against the medtech industry in 2012. But emerging clinical and geographic markets, along with an active M&A market, are providing the industry with some momentum going into 2013.
Stryker Enters China Race With Trauson Bid
The acquisition of Trauson would give Stryker deep roots into the untapped territories of China’s $1.5 billion orthopedics industry, the so-called second- and third-tier markets in lesser developed areas where multinationals haven’t been able to access.